ライフサイエンスコーパス: revascularized

1 ot impact post-LT survival, if appropriately revascularized.

2 s underwent angiography, and 2 patients were revascularized.

3 2; P=0.036) compared with those who were not revascularized.

4 Women were also less likely to be revascularized.

5 ejection fractions; and were more completely revascularized.

6 viable myocardium that cannot be adequately revascularized.

7 t (concordant score: 2.93 +/- 0.07), whereas revascularized (0.5 +/- 0.21) and nontreated segments (-

8 Fewer off-pump patients were effectively revascularized (50.1% versus 63.9% on-pump; P<0.001).

9 ate (5.3%) than those with at least 1 lesion revascularized (7.3%) or left untreated despite FFR</=0.

10 4% had a LVEF </=30%; of the 62% of patients revascularized, 77% had a LVEF </=30%.

11 Of the 38% of patients not revascularized, 84% had a LVEF </=30%; of the 62% of pat

12 Of the 11 who were revascularized, 9 (81.8%) had graft salvage and 2 (18.2%

13 The kidney graft, revascularized after 35 min of warm ischemia, also funct

14 ARITY, we showed that embedded islets became revascularized and integrated with the host's vasculatur

15 oth, or a failure if the corneal surface was revascularized and irregular.

16 predicting ischemia should the CTO vessel be revascularized and potentially affecting the decision on

17 the renal capsule, we found that islets were revascularized and that the transplant recipient vascula

18 During index hospitalization, 5357 were revascularized, and 4589 were managed without revascular

19 By 7 days, tumors were fully revascularized, and the pericyte phenotype returned to b

20 ftable disease in their other arteries, were revascularized as a primary procedure.

21 were eligible to receive PTCA and CABG were revascularized between 1989 and 1992.

22 rs was 93 +/- 6% in the 24 patients who were revascularized but only 49 +/- 15% in the 34 treated med

23 ry territories with significant disease were revascularized by a FitzGibbon A-quality graft to the ma

24 Patients were included if they were revascularized by CABG or PCI-S, had > or = 5 years of f

25 ts, tissue grafts such as skin or islets are revascularized by in-growth of host capillaries and ther

26 value of myocardial viability in surgically revascularized (CABG) patients with left ventricular (LV

27 Consecutive patients with newly revascularized CAD and OSA (apnea-hypopnea index >/=15/h

28 Overall, patient survival in the revascularized CAD group was comparable to angiogram gro

29 transplant, like controls, as were primarily revascularized cardiac allografts.

30 as 46% (78/168) with inducible ischemia were revascularized (coronary bypass surgery, n = 67 or angio

31 atients receiving stents who were completely revascularized (CR) with those who were incompletely rev

32 A successfully revascularized CTO confers a significant 10-year surviva

33 y artery or branch that was not successfully revascularized, divided by the total number of myocardia

34 HAT occurred in 6 of 22 grafts (27.3%) revascularized from the recipient common hepatic artery,

35 nts had a smaller percentage of successfully revascularized index segments than CABG patients (59% ve

36 arized (CR) with those who were incompletely revascularized (IR).

37 ediate benefit may be for the exploration of revascularized islet biology.

38 nsplantation but became a functional part of revascularized islet graft.

39 s from successful animals contained numerous revascularized islets containing a substantial amount of

40 ful CLI patients (97%) with 266 successfully revascularized limbs revealed that bypass surgery occurr

41 The revascularized lung allograft demonstrated a network of

42 Overall, these studies demonstrate that the revascularized lung allograft is responsive to various e

43 the ability of leukocytes to traffic within revascularized lung microvessels by intravital microscop

44 Furthermore, the revascularized microvessels demonstrated the ability to

45 Mean MPRI in revascularized myocardial segments not demonstrating new

46 Five of the 20 patients (25%) were revascularized; of these 5, 2 (40%) had graft salvage, 2

47 ominal wall was removed from the forearm and revascularized on the abdomen (n = 4), or used to close

48 Eleven of 12 patients (91.6%) were revascularized; one patient (8.4%) received no treatment

49 ients with coronary artery disease should be revascularized or treated medically.

50 period, total cardiovascular care costs per revascularized patient decreased by $1680 (95% confidenc

51 hough total cardiovascular-related costs per revascularized patient decreased over this time period,

52 specially in medically treated compared with revascularized patients (100% [8 of 8] vs. 36% [4 of 11]

53 t irrespective of peak troponin levels among revascularized patients (P for interaction=0.004).

54 his analysis was carried out to determine if revascularized patients derive benefit from the 3-hydrox

55 ex hospitalization in 8586 patients (68.0%); revascularized patients had higher peak troponin ratios

56 nts with failed retrograde PCI, successfully revascularized patients showed lower rates of cardiac de

57 Clinical events in revascularized patients were compared between patients o

58 Revascularized patients were more likely to have EF reas

59 ity by race/ethnicity, education, or sex for revascularized patients were observed before or after re

60 Revascularized patients with either percutaneous coronar

61 Revascularized patients with ST-segment-elevation myocar

62 By contrast, in revascularized patients, survival was similar whether my

63 cause mortality rates may be high in elderly revascularized patients, yet cardiac mortality may be le

64 of peak troponin level seem to be minimal in revascularized patients.

65 ival was 84% in nonrevascularized and 95% in revascularized patients.

66 mortality data exist from a large series of revascularized patients.

67 ss-CMR is more cost-effective in symptomatic revascularized patients.

68 patients with a recent AMI (< or =14 days), revascularized percutaneously, with follow-up of > or =3

69 ic in-stent restenosis and were successfully revascularized percutaneously.

70 Pravastatin reduced clinical events in revascularized postinfarction patients with average chol

71 min(-1) . g(-1) . (mm Hg . bpm/10(4))(-1) in revascularized segments and 1.3+/-0.2 mL . min(-1) . g(-

72 Of 109 revascularized segments with severe dysfunction, 46 (42%

73 Of 180 revascularized segments with severe rest dysfunction, re

74 graft vascular thrombosis (15%, two of three revascularized successfully), bacterial and fungal infec

75 rmed coronary disease were less likely to be revascularized than their male counterparts and were twi

76 gher likelihood of ICD implantation for both revascularized (unadjusted, 12.1% versus 2.4%, P<0.001;

77 myocardial infarction and were successfully revascularized underwent cine and ceMRI of their heart w

78 More coronary targets were able to be revascularized using internal thoracic arteries in patie

79 ed patients rather than for those with fully revascularized viable myocardium.

80 anterior-apical wall without the need to be revascularized were enrolled in a prospective, nonrandom

81 outcome after MI, and were less likely to be revascularized when compared with white patients.

82 nsity showed that distorted islets were well revascularized, whereas islets still intact at 1-month p

83 III) single versus multiple coronary systems revascularized with IMAs (single=490 versus multiple=377

84 e (18 to 24 hours) (201)Tl imaging, were not revascularized within 60 days of SPECT, and were followe